BioMarin follows plan in low-risk drug deal with Repligen

BioMarin Pharmaceutical Inc. has found another deal. The San Rafael-based orphan drug specialist (NASDAQ: BMRN) will spend $2 million upfront — with the potential to pay $160 million in milestones — to Repligen Corp...